|
Anaplastic Oligodendroglioma
|
0.580 |
GeneticVariation
|
disease |
BEFREE |
For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype.
|
30878754 |
2019 |
|
Anaplastic Oligodendroglioma
|
0.580 |
GeneticVariation
|
disease |
BEFREE |
In the 2016 WHO classification of diffuse glioma, the diagnosis of an (anaplastic) oligodendroglioma requires the presence of both an IDH mutation (mt) and 1p/19q codeletion, whereas (anaplastic) astrocytoma are divided in IDH wild-type and IDHmt tumors.
|
30072066 |
2018 |
|
Anaplastic Oligodendroglioma
|
0.580 |
Biomarker
|
disease |
BEFREE |
Today, the diagnosis of anaplastic oligodendroglioma requires the presence of both IDH-mt and 1p/19q co-deletion, whereas anaplastic astrocytoma is divided into IDH wild-type ( IDH-wt) and IDH-mt tumors.
|
28640702 |
2017 |
|
Anaplastic Oligodendroglioma
|
0.580 |
GeneticVariation
|
disease |
BEFREE |
Our study indicates that the combination of sequential treatment with radiation and temozolomide might provide a favorable outcome in the case of 1p/19q-codeleted spinal anaplastic oligodendrogliomas and that molecular analysis can be beneficial in guiding treatment strategies, although the impact of IDH mutations on these tumors is still unclear.
|
26352098 |
2016 |
|
Anaplastic Oligodendroglioma
|
0.580 |
GeneticVariation
|
disease |
BEFREE |
The R132H IDH1 mutation was identified in 43/117 tumor samples and R172K IDH2 mutation was detected in only one anaplastic oligodendroglioma.
|
27268645 |
2016 |
|
Anaplastic Oligodendroglioma
|
0.580 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic oligoastrocytoma and anaplastic astrocytoma patients with IDH gene mutation showed similar prognosis with anaplastic oligodendroglioma patients with wild-type IDH gene.
|
24149775 |
2014 |
|
Anaplastic Oligodendroglioma
|
0.580 |
GeneticVariation
|
disease |
BEFREE |
However, no specific imaging pattern could be identified for the 1p/19q-codeleted AO or the IDH-mutated AO.
|
24353325 |
2014 |
|
Anaplastic Oligodendroglioma
|
0.580 |
GeneticVariation
|
disease |
BEFREE |
Studies have identified several molecular abnormalities with clinical or biological relevance to AOD (e.g. t(1;19)(q10;p10), IDH1, IDH2, CIC and FUBP1 mutations).To better characterize the clinical and biological behavior of this tumor type, the creation of a national multicentric network, named "Prise en charge des OLigodendrogliomes Anaplasiques (POLA)," has been supported by the Institut National du Cancer (InCA).
|
23071531 |
2012 |